279 related articles for article (PubMed ID: 31061802)
21. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
22. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis.
Chen J; Ni Y; Sun G; Liao B; Zhang X; Zhao J; Zhu S; Wang Z; Shen P; Zeng H
Front Oncol; 2020; 10():519388. PubMed ID: 33072564
[No Abstract] [Full Text] [Related]
25. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Hammerer P; Manka L
Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
[TBL] [Abstract][Full Text] [Related]
26. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
[TBL] [Abstract][Full Text] [Related]
27. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
Trump DL
Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
[TBL] [Abstract][Full Text] [Related]
29. Management algorithms for metastatic prostate cancer.
Malone S; Shayegan B; Basappa NS; Chi K; Conter HJ; Hamilton RJ; Hotte SJ; Saad F; So AI; Park-Wyllie L; Hew H; McLeod D; Gotto G
Can Urol Assoc J; 2020 Feb; 14(2):50-60. PubMed ID: 31039111
[TBL] [Abstract][Full Text] [Related]
30. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
32. Sequencing of agents for castration-resistant prostate cancer.
Hurwitz M; Petrylak DP
Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
[TBL] [Abstract][Full Text] [Related]
33. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.
Gartrell BA; Saad F
Ther Adv Urol; 2015 Aug; 7(4):194-202. PubMed ID: 26445599
[TBL] [Abstract][Full Text] [Related]
34. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
35. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
36. Current therapeutic options in metastatic castration-resistant prostate cancer.
Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
[TBL] [Abstract][Full Text] [Related]
37. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of metastatic, castration-resistant prostate cancer].
von Amsberg G; Merseburger AS
Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
[TBL] [Abstract][Full Text] [Related]
39. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
